Estevan Kiernan, MS
Predicting who will respond to chemo
REVO Oncology
Seattle, Texas, United States
About
Estevan Kiernan is the Founder and CEO of REVO Oncology, where he is focused on bringing predictive insight to one of the most widely used yet least understood areas of cancer treatment, chemotherapy response. He has spent over 15 years in diagnostics across Illumina, Abbott, and Thermo Fisher Scientific, leading the launch and commercialization of more than 20 clinical products. At Illumina, Estevan spent nearly a decade bringing translational applications into the clinic. Working at the intersection of clinical development, market access, and commercial execution, Estevan played a pivotal role in Illumina's position in CPG, MRD and clinical WGS in Heme and solid tumor cancers. His work has supported programs changing NCCN guidelines multiple times over, NEJM and Nature publications, and working with leading cancer institutions to build a portfolio of NGS-based IP for future product integration. At REVO, he leads the strategy of establishing a pan-cancer chemoresponse platform that can be integrated into on-market genomic infrastructure. His singular focus is to achieve the vision of bringing personalized medicine to all cancer patients in the first line setting.
Companies
REVO Oncology
Predict who will respond to chemotherapy before the patient is treated for all cancer.
Only accessible to MedStartr community members.
Join now
Roles
Connect with Estevan
Every way to reach Estevan, and what each one does.
Send a message
Start a private conversation with Estevan on MedStartr.
Join MedStartr to message EstevanHire Estevan
Send a structured offer — what for, budget, type, rate and a description. It arrives as a private message; nobody is charged anything.
Join MedStartr to hire Estevan